DOI,paper_doi,paper_title_x,count_atlas,Publication_PMID,Publication_link,count_lnpdb,lnp_id,ionizable_lipid,peg_lipid,sterol_lipid,helper_lipid,lipid_molar_ratio,particle_size_nm_std,pdi_std,zeta_potential_mv_std,encapsulation_efficiency_percent_std,loading_capacity_std,target_type,nucleic_acid_sequence,peg_lipid_original,ionizable_lipid_original,helper_lipid_original,sterol_lipid_original,ionizable_lipid_smiles,peg_lipid_smiles,sterol_lipid_smiles,helper_lipid_smiles,synthesis_info,bioactivity_profile,paper_title_y,paper_authors,paper_journal,paper_year
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,862,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:9.4:42.7:1.6,183.3 ± 1.5,,,~80,NP:6(molar),mRNA,firefly_luciferase,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Manual mixing; device_used: Pipette mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: 1200; temperature_condition: Room temperature; post_processing: Buffer dilution to reduce ethanol concentration; sterilization: ; storage_buffer: Room temperature for 20 min,"cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 1 μg mRNA per mouse (in vivo), 100 ng mRNA per well (in vitro); gene_expression_result: Standard reference for comparison; biodistribution_result: High liver, skin, lymph node accumulation; toxicity_profile: No significant toxicity in mice",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,863,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:9.4:42.7:1.6,~70,<0.2,,~80,NP:6(molar),mRNA,firefly_luciferase,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation (30,000 Da MWCO) at 1500g, 4°C; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 1 μg mRNA per mouse (in vivo), 100 ng mRNA per well (in vitro); gene_expression_result: 9.36-fold increase vs manual mixing in HepG2, 4.92-fold in A549; biodistribution_result: High liver, skin, lymph node accumulation; toxicity_profile: No significant toxicity in mice",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,864,ALC-0315,DMG-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,~65,<0.2,,~80,NP:6(molar),mRNA,firefly_luciferase,DMG-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; dose: 100 ng mRNA per well (in vitro); gene_expression_result: Comparable to ALC-0159; toxicity_profile: Cell viability >90%",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,865,ALC-0315,DMG-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,~65,<0.2,,~80,NP:6(molar),mRNA,firefly_luciferase,DMG-C-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; dose: 100 ng mRNA per well (in vitro); gene_expression_result: 1.70-fold higher than DMG-PEG in HepG2, 1.25-fold in A549; toxicity_profile: Cell viability >90%",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,866,ALC-0315,DSG-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,~65,<0.2,,~80,NP:6(molar),mRNA,firefly_luciferase,DSG-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; dose: 100 ng mRNA per well (in vitro); gene_expression_result: 20.57-fold lower than DMG-PEG in HepG2; toxicity_profile: Cell viability >90%",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,867,ALC-0315,C8-Ceramide-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,70.6 ± 0.5,,,~80,NP:6(molar),mRNA,firefly_luciferase,C8-Ceramide-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 1 μg mRNA per mouse (in vivo), 100 ng mRNA per well (in vitro); gene_expression_result: Lower than C16-Ceramide-PEG via microfluidic mixing; biodistribution_result: Mainly injection site and lymph node, minimal liver accumulation; toxicity_profile: No significant toxicity in mice; cytokine_response: Negligible anti-PEG IgM levels",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,868,ALC-0315,C16-Ceramide-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,~75,,,~80,NP:6(molar),mRNA,firefly_luciferase,C16-Ceramide-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 1 μg mRNA per mouse (in vivo), 100 ng mRNA per well (in vitro); gene_expression_result: Higher than C8-Ceramide-PEG via microfluidic mixing; biodistribution_result: High liver accumulation, highest liver specificity; toxicity_profile: No significant toxicity in mice; cytokine_response: Higher anti-PEG IgM than C8-Ceramide-PEG and ALC-0159",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,869,ALC-0315,DMPE-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,,,,~80,NP:6(molar),mRNA,firefly_luciferase,DMPE-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; dose: 100 ng mRNA per well (in vitro); gene_expression_result: 49.25-fold higher than DSPE-PEG in HepG2; toxicity_profile: Cell viability >90%",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,870,ALC-0315,DSPE-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,92.8,,,60,NP:6(molar),mRNA,firefly_luciferase,DSPE-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 1 μg mRNA per mouse (in vivo), 100 ng mRNA per well (in vitro); gene_expression_result: Lowest among all tested PEG-lipids; biodistribution_result: Lower liver accumulation, higher lymph node specificity; toxicity_profile: No significant toxicity in mice; cytokine_response: Highest anti-PEG IgM production among tested formulations",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,871,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:9.4:42.7:1.6,~80,,,,NP:6(molar),mRNA,sars_cov2_spike,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 500 ng mRNA per mouse (prime-boost strategy); gene_expression_result: Highest spike protein expression among tested formulations; toxicity_profile: No weight loss, normal biochemical markers; cytokine_response: ~60% RBD-ACE2 inhibition after 1st dose, >90% after 2nd dose",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,872,ALC-0315,C8-Ceramide-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,~80,,,,NP:6(molar),mRNA,sars_cov2_spike,C8-Ceramide-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 500 ng mRNA per mouse (prime-boost strategy); gene_expression_result: Comparable to C16-Ceramide-PEG; toxicity_profile: No weight loss, normal biochemical markers; cytokine_response: ~60% RBD-ACE2 inhibition after 1st dose, >90% after 2nd dose, negligible anti-PEG response",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,873,ALC-0315,C16-Ceramide-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,90.1 ± 1.0,,,,NP:6(molar),mRNA,sars_cov2_spike,C16-Ceramide-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 500 ng mRNA per mouse (prime-boost strategy); gene_expression_result: Comparable to C8-Ceramide-PEG and ALC-0159; toxicity_profile: No weight loss, normal biochemical markers; cytokine_response: ~60% RBD-ACE2 inhibition after 1st dose, >90% after 2nd dose, moderate anti-PEG response",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
10.1016/j.jconrel.2025.01.071,https://doi.org/10.1016/j.jconrel.2025.01.071,Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,13,39875076.0,https://doi.org/10.1016/j.jconrel.2025.01.071,96,874,ALC-0315,DSPE-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,111.2 ± 0.3,,,,NP:6(molar),mRNA,sars_cov2_spike,DSPE-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 500 ng mRNA per mouse (prime-boost strategy); gene_expression_result: Lowest spike protein expression, especially in HepG2 cells; toxicity_profile: No weight loss, normal biochemical markers; cytokine_response: Lower vaccination efficacy - 29.9% RBD-ACE2 inhibition after 1st dose, >90% after 2nd dose, highest anti-PEG response",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",Journal of Controlled Release,2025.0
